The Effect on Mucosal Healing With Pentasa Sachet in Mild to Moderate Active "Drug: Crohn's Disease"
Study Details
Study Description
Brief Summary
The purpose of this study is to visualize the healing effect on mucosal lesions with Pentasa Sachet 4g in patients with mild to moderate active small bowel CD by video capsule endoscopy.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 3 |
Detailed Description
The purpose of this study is to visualize the healing effect on mucosal lesions with Pentasa Sachet 4g in patients with mild to moderate active small bowel CD by video capsule endoscopy
Study Design
Outcome Measures
Primary Outcome Measures
- Mucosal changes, (measured as number, type and localization of small bowel mucosal lesions detected by VCE) from baseline (i.e. < 7 days prior to inclusion), and after 6 and 12 weeks´ treatment with 4g Pentasa Sachet [12 weeks]
Secondary Outcome Measures
- CDAI changes and laboratory changes [12 weeks]
Eligibility Criteria
Criteria
4.2 Inclusion Criteria
-
Patients who have signed the informed consent form
-
Patients with performed complete VCE < 7 days prior to inclusion and diagnosed clinically active mild to moderate small bowel CD and no stricture on previous examinations, as previously proven by barium small bowel follow through, enteroclysis and / or patency test capsule.
-
Patients between 18 - 70 years of age.
4.3 Exclusion Criteria
-
Patients with evidence of other forms of inflammatory small bowel bowel disease, idiopathic proctitis or infectious disease.
-
Patients with known small bowel strictures from previous examinations with for instance barium small bowel follow through, enteroclysis and / or patency capsule test.
-
Patients with pacemaker due to lack of VCE interaction data.
-
Patients who cannot undergo study procedures due to swallowing disorders.
-
Planned or actual pregnancy or lactation.
-
Women of child-bearing potential who are not using an effective method of contraception, in the opinion of the investigator.
-
Patients receiving maintenance treatment (p.o.) with total daily doses above 2.0g of sulphasalazine, mesalazine or 4-ASA, for 30 days prior to entry into the study.
-
Chronic use of non-steroidal anti-inflammatory drugs (oral and/or rectal routes) in 30 days prior to inclusion in the study (chronic use is defined as drug intake for a minimum of 3 consecutive days).
-
Intake of corticosteroids (oral and/or rectal routes) within the 30 days prior to enrolment in the study.
-
Patients receiving any immunosuppressive (azathioprine, 6-MP, etc) agents during 30 days prior to study enrolment.
-
Patients receiving any Crohn specific biological agents (TNF-alfa) during the last year prior to study enrolment.
-
Patients with any other disease or condition which may interfere with study assessments as judged by the investigator.
-
Alcoholism or drug addiction. 15. Patients participating or having participated in another clinical study in the previous 30 days.
-
Patients with severe renal/hepatic impairment (see section 5.6) as judged by the investigator.
-
Patients who are allergic to salicylate or 5-ASA derivatives. 18. Patients who are unlikely to comply with the protocol. 19. Any patient who has previously taken part in this study. 20. Patients who are unable to write or read local language
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Medicine, Malmö University Hospital | Malmo | Malmö | Sweden | SE-205 02 |
Sponsors and Collaborators
- Ferring Pharmaceuticals
Investigators
- Study Director: Clinical Development Support, Ferring Pharmaceuticals
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- FE999907 CS004